Similar articles

• Hepatorenal syndrome: The last pieces of the puzzle or not yet?

  Graupera I, Ginès P. Graupera I, et al. Hepatology. 2015 Aug;62(2):352-4. doi: 10.1002/hep.27829. Epub 2015 May 29. Hepatology. 2015. PMID: 25846649 No abstract available.
• Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.

  Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Cavallin M, et al. Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13. Hepatology. 2015. PMID: 25644760 Clinical Trial.
• [Vasoconstrictors in the treatment of hepatorenal syndrome].

  Ortega R, Calahorra B, Ginès P. Ortega R, et al. Nefrologia. 2002;22 Suppl 5:56-61. Nefrologia. 2002. PMID: 12107919 Review. Spanish. No abstract available.
• [Hepatorenal syndrome: a new therapeutic approach?].

  Gerbes AL, Gülberg V. Gerbes AL, et al. Z Gastroenterol. 1999 Sep;37(9):983-5. Z Gastroenterol. 1999. PMID: 10522370 Clinical Trial. German. No abstract available.
• Comparative efficacy of pharmacological strategies for management of type 1 hepatorenal syndrome: a systematic review and network meta-analysis.

  Facciorusso A, Chandar AK, Murad MH, Prokop LJ, Muscatiello N, Kamath PS, Singh S. Facciorusso A, et al. Lancet Gastroenterol Hepatol. 2017 Feb;2(2):94-102. doi: 10.1016/S2468-1253(16)30157-1. Epub 2016 Dec 2. Lancet Gastroenterol Hepatol. 2017. PMID: 28403995 Review.